行情

BLUE

BLUE

蓝鸟生物
NASDAQ

实时行情|Nasdaq Last Sale

60.90
-0.88
-1.42%
盘后: 60.60 -0.3 -0.49% 18:34 08/13 EDT
开盘
61.59
昨收
61.78
最高
63.19
最低
60.89
成交量
98.52万
成交额
--
52周最高
124.16
52周最低
38.95
市值
40.33亿
市盈率(TTM)
-5.1777
分时
5日
1月
3月
1年
5年

分析师评级

23位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测BLUE价格均价为103.67,最高价位196.00,最低价为68.00。

EPS

BLUE 新闻

更多
Morgan Stanley Maintains Equal-Weight on bluebird bio, Lowers Price Target to $68
Morgan Stanley maintains bluebird bio (NASDAQ:BLUE) with a Equal-Weight and lowers the price target from $73 to $68.
Benzinga · 3天前
Why Bluebird Bio's Stock Is Trading Higher Today
Bluebird Bio (NASDAQ: BLUE) shares are trading higher on Thursday after the company reported second-quarter EPS and sales results up from last year. Wedbush also maintained its Outperform rating on the stock.View more earnings on BLUEBluebird Bio is a clinical
Benzinga · 08/06 15:42
bluebird bio EPS beats by $2.16, beats on revenue
bluebird bio (NASDAQ:BLUE): Q2 GAAP EPS of -$0.36 beats by $2.16. Revenue of $198.89M (+1395.4% Y/Y) beats by $117.82M. Press Release
seekingalpha · 08/06 02:02
Bluebird Bio (BLUE) Reports Q2 Loss, Tops Revenue Estimates
Bluebird (BLUE) delivered earnings and revenue surprises of 81.15% and 95.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/06 00:25
bluebird bio Reports Second Quarter 2020 Financial Results and Recent Operational Progress
bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the second quarter ended June 30, 2020 and shared recent operational progress.
Business Wire · 08/05 20:10
Why Earnings Season Could Be Great for bluebird bio (BLUE)
bluebird bio (BLUE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Zacks · 08/05 12:41
bluebird bio Announces August Investor Event
bluebird bio, Inc. (NASDAQ: BLUE) today announced members of the management team will participate in the Canaccord Genuity 40th Annual Growth Conference, Wednesday, August 12, at 10:30 a.m. ET.
Business Wire · 07/31 12:00
Bluebird Bio (BLUE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Bluebird (BLUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/30 16:33

所属板块

生物技术和医学研究
+0.99%
制药与医学研究
-0.06%

热门股票

代码
价格
涨跌幅

BLUE 简况

bluebird bio, Inc.是一家生物技术公司。该公司专注于开发治疗严重遗传病及罕见病的转换基因疗法以及T细胞免疫疗法。基因治疗临床计划包括用于治疗输血型B型地中海贫血(TDT)和严重镰状细胞疾病的候选产品LentiGlobin,以及治疗肾上腺脑白质失养症(一种罕见遗传性神经系统疾病)的候选产品Lenti-D。该公司运用慢病毒基因转移及T细胞工程开展肿瘤学计划,专注于开发T细胞免疫疗法(包括嵌合抗原受体及T细胞受体疗法)。其肿瘤学计划bb2121是一种嵌合抗原受体T细胞候选产品,在多发性骨髓瘤中靶向B细胞成熟抗原(BCMA)。该公司还提供在生产线中运用megaTAL基因编辑技术(即归巢内切核酸酶基因编辑技术)的探索研究计划。
展开

微牛提供bluebird bio Inc(NASDAQ-BLUE)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的BLUE股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易BLUE股票基本功能。